Expression and Prognostic Analyses of ITGA3, ITGA5, and ITGA6 in Head and Neck Squamous Cell Carcinoma.

Abstract

BackgroundThe landscape of head and neck cancers has changed with improvements in standard therapy; however, it is necessary to exploit advanced genomic approaches to identify novel diagnostic and prognostic biomarkers for head and neck squamous cell carcinoma (HNSC). ITGA3, ITGA5, and ITGA6, members of the integrin family of proteins, play active roles in cytoskeletal organization and cell migration, proliferation, and survival. However, the expression patterns and prognostic values of ITGA3, ITGA5, and ITGA6 in head and neck squamous cell carcinoma remain unclear.Material/MethodsDifferent expression patterns and prognostic values of ITGA3, ITGA5, and ITGA6 were analyzed in patients with HNSC using various databases, including ONCOMINE, GEPIA, TIMER, HPA, Kaplan-Meier Plotter, GEO, and TCGA.ResultsExpression levels of ITGA3, ITGA5, and ITGA6 were substantially increased in patients with HNSC. Additionally, higher expression levels of ITGA3, ITGA5, and ITGA6 were associated with worse overall survival in patients with HNSC, and higher levels of ITGA3 correlated with a worse relapse-free survival.ConclusionsITGA3, ITGA5, and ITGA6 are potential diagnostic and prognostic biomarkers for HNSC. In particular, IGTA5 might be used as a significant independent prognostic factor in this cancer.